RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07099274, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. At least one measurable target lesion confirmed by screening imaging per RECIST v1.1;

    Inclusion criterion 8

    Histologically/cytologically confirmed fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma;

    Inclusion criterion 12

  3. Child-Pugh class A or class B (score ≤7) without hepatic encephalopathy history;

    Inclusion criterion 6

  4. ECOG performance status 0-2;

    Inclusion criterion 5

  5. Active HBV/HCV infection requires ongoing antiviral therapy; k.Fertile patients must use highly effective contraception with partners during treatment and ≥180 days post-last dose.

    Inclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07099274, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Comprehension and voluntary signing of the study's informed consent form;
  • Age ≥18 years, any gender;
  • Histologically or clinically confirmed hepatocellular carcinoma;
  • Documented failure or intolerance to first-line therapy with PD-1/PD-L1 inhibitor plus bevacizumab;
  • ECOG performance status 0-2;
  • Child-Pugh class A or class B (score ≤7) without hepatic encephalopathy history;
  • Life expectancy ≥3 months;
  • At least one measurable target lesion confirmed by screening imaging per RECIST v1.1;
  • Adequate organ and bone marrow function within 7 days prior to initial study treatment;
  • Active HBV/HCV infection requires ongoing antiviral therapy; k.Fertile patients must use highly effective contraception with partners during treatment and ≥180 days post-last dose.

2.Exclusion Criteria:

  • Inability to comply with the study protocol or procedures;
  • Histologically/cytologically confirmed fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma;
  • History of liver transplantation or planned transplantation;
  • Presence of central nervous system metastases and/or leptomeningeal carcinomatosis;
  • Baseline imaging showing Vp4 portal vein tumor thrombosis;
  • Hypersensitivity to any study drug components or history of severe allergic reactions;
  • Concurrent HBV and HCV co-infection;
  • Clinically significant ascites requiring intervention during screening;
  • Concurrent use of other investigational drugs or participation in another clinical trial within 4 weeks prior to enrollment;
  • Esophageal/gastric variceal bleeding due to portal hypertension within 6 months before treatment initiation, or high-risk varices on endoscopy within 3 months;
  • Current interstitial lung disease (ILD), history of steroid-required ILD, or other pulmonary fibrosis/organizing pneumonia affecting immune-related pulmonary toxicity assessment;
  • Uncontrolled hypertension (SBP≥160 mmHg and/or DBP≥100 mmHg despite medication), coronary artery disease, arrhythmias, or heart failure (NYHA Class ≥II);
  • Uncontrolled clinically significant infections requiring IV antimicrobial therapy;
  • Proteinuria ≥2+ (≥1.0g/24h);
  • History of hemorrhagic tendency regardless of severity within 2 months prior to enrollment;
  • Arterial/venous thromboembolic events within 12 months before treatment initiation (e.g., cerebrovascular accident including TIA);
  • Acute myocardial infarction, acute coronary syndrome, or CABG within 6 months before treatment;
  • Unhealed fractures or chronic non-healing wounds;
  • Coagulopathy, bleeding diathesis, or current therapeutic anticoagulation;
  • Other malignancies within 5 years except curatively resected basal/squamous cell skin carcinoma or cervical carcinoma in situ;
  • Active autoimmune disease or autoimmune disease history requiring immunosuppression within 4 weeks prior to enrollment;
  • Prior allogeneic bone marrow or solid organ transplantation;
  • Investigator assessment of ineligibility based on medical/safety reasons.

Quoted from ClinicalTrials.gov, NCT07099274, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07099274, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07099274